Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors (Q34674491)

3 August 2017

1 reference

title

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors (English)

1 reference

3 August 2017

5

John J P Kastelein

1 reference

3 August 2017

author name string

Anke Hilse Maitland-van der Zee

1

1 reference

3 August 2017

Olaf H Klungel

2

1 reference

3 August 2017

Bruno H Ch Stricker

3

1 reference

3 August 2017

W M Monique Verschuren

4

1 reference

3 August 2017

Hubertus G M Leufkens

6

1 reference

3 August 2017

Anthonius de Boer

7

1 reference

3 August 2017

publication date

1 August 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

163

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

213-222

1 reference

Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Genomic medicine and the future of health care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Therapeutic lessons from pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Pharmacogenomics. Interview by Clare Thompson

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The interface between pharmacoepidemiology and pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Reverse cholesterol transport--a review of the process and its clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Role of ABC1 gene in cholesterol efflux and atheroprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Tangier disease as a test of the reverse cholesterol transport hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

APO E gene and gene-environment effects on plasma lipoprotein-lipid levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

A common variant in the gene for lipoprotein lipase (Asp9-->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

Assessing the cost-effectiveness of pharmacogenomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2801%2900725-0

10.1016/S0021-9150(01)00725-0

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference